William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Department of Clinical Pharmacology, Cardiovascular Medicine, Barts Health NHS Trust, London, UK.
Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):100-103. doi: 10.1093/ehjcvp/pvab063.
Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.
药物基因组学有望推动心血管治疗的发展，但在实施过程中仍存在实际障碍。在欧洲，这些障碍尤其需要探讨，因为欧洲各国在人口、资源和专业知识方面存在差异，伦理法律框架也不同。欧洲各国医疗服务的差异带来了挑战，但也为药物基因组学的实施提供了合作机会。临床劳动力技能提升已经在进行中，但需要大量投入。数字基础设施和临床支持工具可能会被证明是至关重要的。重要的是，广泛的实施应该有助于缩小而不是扩大人群之间健康平等方面现有的差距。本观点补充了关于心血管药物基因组学的工作组立场文件，以解决这些重要主题。
